EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Circulating tumour DNA as a predictor of survival of patients with diffuse large B‐cell lymphoma in a daily practice

Prokop Vodicka iD, Iva Hamova, Adriana Velasova, Kristyna Kupcova, Petra Zemankova, Petr Nehasil, Anton Tkachenko, Katerina Lochovska, Sarka Muzikova, Sarka Hrabetova, Jitka Dlouha, Petra Blahovcova und 10 weitere

British Journal of Haematology · 2025

DOI: 10.1111/bjh.70128 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Prokop Vodicka und 21 weiteren Autor:innen. Beteiligte Einrichtung: First Department of Medicine-Hematology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Circulating Tumor DNA, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health of the Czech Republic, National Institute for Cancer Research, MEYSCR via Charles University Cooperatio program - Biology and Hematology-Onco.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Circulating tumour DNA (ctDNA) is a promising biomarker for diffuse large B-cell lymphoma (DLBCL) risk stratification and treatment response assessment, but real-world studies were limited. Using a targeted sequencing approach (521-gene panel), we showed that (1) baseline ctDNA level correlated with tumour burden and was an independent predictor of treatment outcome, (2) achievement of minimal residual disease (MRD) negativity was associated with a better treatment outcome and (3) interim MRD-positivity combined with positron emission tomography/computed tomography scan-positivity identified a high-risk subgroup of DLBCL patients. Baseline ctDNA level and treatment related achievement of MRD negativity are valuable prognostic tools in DLBCL to improve risk stratification in routine clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseCirculating Tumor DNABiomarkers, TumorHumansFemaleMaleMiddle AgedNeoplasm, ResidualAgedAdultPrognosisPositron Emission Tomography Computed TomographyAged, 80 and overAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

circulating tumour DNAdiffuse large B‐cell lymphomaminimal residual diseaserisk stratificationtreatment response evaluation

Substanzen

Circulating Tumor DNABiomarkers, Tumor

Autor:innen und Institutionen

  • First Department of Medicine-Hematology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
  • First Faculty of Medicine, BIOCEV, Charles University, Vestec, Czech Republic.
  • First Faculty of Medicine, Institute of Medical Biochemistry and Laboratory Diagnostics, Charles University and General University Hospital in Prague, Prague, Czech Republic.
  • First Faculty of Medicine, Institute of Pathological Physiology, Charles University, Prague, Czech Republic.
  • Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
  • The Czech Lymphoma Study Group, Prague, Czech Republic.

ORCID-Profile: Prokop Vodicka, Pavel Klener, Marek Trneny, Ondrej Havranek

Förderung

  • Ministry of Health of the Czech Republic
  • National Institute for Cancer Research
  • MEYSCR via Charles University Cooperatio program - Biology and Hematology-Onco
  • Ministerstvo Zdravotnictví Ceské Republiky

Zitieren

APA

Vodicka, P., Hamova, I., Velasova, A., Kupcova, K., Zemankova, P., Nehasil, P., Tkachenko, A., Lochovska, K., Muzikova, S., Hrabetova, S., Dlouha, J., Blahovcova, P., Frouz, T., Senavova, J., Dlouha, L., Polgarova, K., Klanova, M., Salkova, J., Benesova, K., …, & Havranek, O. (2025). Circulating tumour DNA as a predictor of survival of patients with diffuse large B‐cell lymphoma in a daily practice. British Journal of Haematology. https://doi.org/10.1111/bjh.70128

Vancouver

Vodicka P, Hamova I, Velasova A, Kupcova K, Zemankova P, Nehasil P, et al. Circulating tumour DNA as a predictor of survival of patients with diffuse large B‐cell lymphoma in a daily practice. British Journal of Haematology. 2025. doi:10.1111/bjh.70128

BibTeX
@article{Vodicka2025,
  author = {Vodicka, Prokop and Hamova, Iva and Velasova, Adriana and Kupcova, Kristyna and Zemankova, Petra and Nehasil, Petr and Tkachenko, Anton and Lochovska, Katerina and Muzikova, Sarka and Hrabetova, Sarka and Dlouha, Jitka and Blahovcova, Petra and Frouz, Tomas and Senavova, Jana and Dlouha, Lucie and Polgarova, Kamila and Klanova, Magdalena and Salkova, Jana and Benesova, Katerina and Klener, Pavel and Trneny, Marek and Havranek, Ondrej},
  title = {Circulating tumour DNA as a predictor of survival of patients with diffuse large B‐cell lymphoma in a daily practice},
  journal = {British Journal of Haematology},
  year = {2025},
  doi = {10.1111/bjh.70128}
}
Kostenlos starten →